• Autonomix posted a net loss of USD 16.7 million for fiscal 2026, with operating expenses rising 47% to USD 17.03 million.
• R&D expense climbed 51% to USD 7.14 million, driven by higher clinical trial and product development costs.
• G&A costs increased 44% to USD 9.89 million on higher stock-based compensation and legal and professional fees.
• Cash totaled USD 7 million at March 31, 2026, with USD 5.9 million of working capital; management expects funding into but not beyond Q4 2026.
• The company said it needs USD 25 million to USD 32 million of additional financing to fund operations through an initial commercial launch for pancreatic cancer pain.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autonomix Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-018573), on May 27, 2026, and is solely responsible for the information contained therein.